UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorpora ...

NeoGenomics Conference Call Prepared Remarks Good morning. I'd like to welcome everyone to NeoGenomics' 2021 Third Quarter conference call. Joining me for this call from our new headquarters in Fort Myers are George Cardoza, President and Chief Operating Officer of our Lab Operations, Doug Brown, our Chief Strategy and Corporate Development Officer and Charlie Eidson, our Director of Investor Relations. Joining on the call via phone from California is Dr. Gina Wallar, President of our Pharma Services Divisi ...

NeoGenomics, Inc. (NASDAQ:NEO) Q3 2021 Earnings Conference Call November 4, 2021 8:30 AM ET Company Participants Mark Mallon - Chief Executive Officer George Cardoza - President, Lab Operations and COO Doug Brown - Chief Strategy and Corporate Development Officer Charlie Eidson - Director, Investor Relations Dr. Gina Wallar - President, Pharma Services Division Dr. Clive Morris - President, Inivata Kathryn McKenzie - Chief Financial Officer Bill Bonello - President, Informatics Conference Call Participants ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporation ...

NeoGenomics, Inc. (NASDAQ:NEO) Q2 2021 Earnings Conference Call August 6, 2021 8:30 AM ET Company Participants Doug VanOort - Chairman Mark Mallon - CEO Kathryn McKenzie - CFO George Cardoza - President, Pharma Services Division Bill Bonello - President, Informatics Division Doug Brown - Chief Strategy and Corporate Development Officer Clive Morris - CEO, Inivata Conference Call Participants David Westenberg - Guggenheim Brian Weinstein - William Blair Alex Nowak - Craig-Hallum Capital Group Mark Massaro - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35756 NEOGENOMICS, INC. (Exact name of registrant as specified in its charter) Nevada 74-2897368 (State or other jurisdiction of incorporatio ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------------------|-------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | NeoGenomics Investor Presentation | | | | | | | | | | May 2021 | | | | | | | | | 1 and and and the see and 2 Forward-Looking Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or ...

NeoGenomics, Inc. (NASDAQ:NEO) Q1 2021 Earnings Conference Call May 5, 2021 8:30 AM ET Company Participants Doug VanOort - Chairman Mark Mallon - Chief Executive Officer Kathryn McKenzie - Chief Financial Officer George Cardoza - President, Pharma Services Division Bill Bonello - President, Informatics Division Doug Brown - Chief Strategy and Corporate Development Officer Charlie Eidson - Manager of Investor Relations Clive Morris - Chief Executive Officer, Inivata Conference Call Participants Puneet Souda ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------------------|-------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | NeoGenomics Investor Presentation | | | | | | | | | | February 2021 | | | | | | | | | 1 and and and the see and 2 Forward-Looking Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to se ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Nevada 74-2897368 For the transition period from _________ to __________ (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Commission File Number: 001-35756 127 ...